Clearmind to Test MEAI with Tirzepatide in 12-Month Obesity Study
Clearmind Medicine has signed a research agreement with Hebrew University to fund a 12-month preclinical study evaluating MEAI’s metabolic efficacy in combination with and as maintenance therapy after tirzepatide in diet-induced obese mice. Prior results showed 15–20% weight reduction via increased energy expenditure.
1. Research Agreement Signed
Clearmind Medicine has partnered with Yissum Research Development Company at Hebrew University to launch a new research agreement funding a 12-month preclinical study. The collaboration will evaluate MEAI (CMND-100) in combination with and as a maintenance therapy after tirzepatide in diet-induced obese mice.
2. Study Design and Objectives
The study, led by Professor Joseph Tam’s Obesity and Metabolism Laboratory, will assess additive or synergistic metabolic effects of MEAI with tirzepatide and examine MEAI’s potential to attenuate post-tirzepatide weight regain across multiple dosages over 12 months.
3. Prior Preclinical Results
In earlier work with the same laboratory, MEAI demonstrated 15–20% body weight reduction in DIO mice primarily through enhanced energy expenditure and fat utilization, while preserving lean muscle mass and improving glucose homeostasis and liver health.
4. Market Opportunity and Rationale
The incretin-based therapy market reached $50–66 billion in 2025 and is projected to reach $170–185 billion by 2033, creating demand for complementary treatments to sustain weight loss durability and metabolic benefits beyond appetite suppression.